Nivolumab Combination Therapy and Safety Management in Cancer Treatment

Oncology
Nivolumab-based combination therapy has expanded treatment options across several cancers, but combining immune checkpoint inhibitors or targeted agents can increase treatment-related toxicities. Understanding treatment selection, dosing schedules, baseline assessment and ongoing monitoring is essential for safe clinical practice. Particular attention is needed to immune-related adverse events affecting the skin, gastrointestinal tract, liver, lungs, endocrine system, kidneys and cardiovascular system. Early recognition, appropriate toxicity grading, timely treatment interruption and corticosteroid-based management can help prevent serious complications and support treatment continuity. Patient education, multidisciplinary coordination and continued monitoring after treatment discontinuation are also important components of comprehensive safety management. Please participate in the survey and share your opinion on nivolumab combination therapy and safety management in cancer treatment.
Do you think early recognition and management of immune-related adverse events can improve treatment continuity and patient outcomes?
- Strongly agree
- Agree
- Disagree
- Not sure
In your opinion, which Nivolumab dose is most appropriate during combination induction therapy?
- 1 mg/kg every 3 weeks
- 3 mg/kg every 3 weeks
- 240 mg every 2 weeks
- 480 mg every 4 weeks